Stevanato Group S.p.A. (NYSE:STVN) Shares Purchased by Bamco Inc. NY

Bamco Inc. NY lifted its stake in Stevanato Group S.p.A. (NYSE:STVN - Free Report) by 7.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,818,181 shares of the company's stock after acquiring an additional 133,000 shares during the period. Bamco Inc. NY owned 0.60% of Stevanato Group worth $39,618,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the stock. M&T Bank Corp purchased a new stake in shares of Stevanato Group during the fourth quarter valued at $572,000. Mutual of America Capital Management LLC purchased a new stake in Stevanato Group during the 4th quarter valued at about $13,848,000. Advantage Alpha Capital Partners LP increased its holdings in shares of Stevanato Group by 27.3% in the fourth quarter. Advantage Alpha Capital Partners LP now owns 293,865 shares of the company's stock valued at $6,403,000 after purchasing an additional 63,041 shares during the period. Allianz SE purchased a new position in shares of Stevanato Group in the fourth quarter worth about $748,000. Finally, Zions Bancorporation N.A. lifted its holdings in shares of Stevanato Group by 29.7% during the fourth quarter. Zions Bancorporation N.A. now owns 68,017 shares of the company's stock worth $1,482,000 after purchasing an additional 15,555 shares during the period.

Analyst Ratings Changes

STVN has been the subject of several research reports. Stephens upgraded shares of Stevanato Group to a "strong-buy" rating in a research note on Monday, April 21st. William Blair restated an "outperform" rating on shares of Stevanato Group in a research report on Friday, March 7th. Finally, UBS Group lowered their price target on shares of Stevanato Group from $24.00 to $23.50 and set a "neutral" rating on the stock in a report on Friday, March 7th. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Stevanato Group has an average rating of "Moderate Buy" and a consensus target price of €25.70 ($28.88).

Stevanato Group Stock Performance

NYSE STVN traded up €1.44 ($1.62) during mid-day trading on Friday, reaching €23.92 ($26.88). 685,300 shares of the stock were exchanged, compared to its average volume of 351,034. The company has a market capitalization of $7.24 billion, a P/E ratio of 50.89, a P/E/G ratio of 7.18 and a beta of 0.51. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81. The business's 50 day moving average is €21.12 and its 200-day moving average is €20.98. Stevanato Group S.p.A. has a 1 year low of €16.56 ($18.61) and a 1 year high of €24.90 ($27.98).

Stevanato Group (NYSE:STVN - Get Free Report) last announced its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, meeting the consensus estimate of €0.20 ($0.22). The firm had revenue of €352.68 million during the quarter, compared to analyst estimates of €346.26 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. On average, equities research analysts forecast that Stevanato Group S.p.A. will post 0.5 EPS for the current fiscal year.

Stevanato Group Increases Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, July 17th. Investors of record on Thursday, June 5th will be given a dividend of $0.0613 per share. This represents a dividend yield of 0.3%. This is a boost from Stevanato Group's previous annual dividend of $0.05. The ex-dividend date of this dividend is Thursday, June 5th. Stevanato Group's payout ratio is presently 12.50%.

Stevanato Group Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.